HRP20131203T1 - Linije matiäśnih stanica iz paäśjih embrija za proizvodnju virusnih cjepiva - Google Patents
Linije matiäśnih stanica iz paäśjih embrija za proizvodnju virusnih cjepiva Download PDFInfo
- Publication number
- HRP20131203T1 HRP20131203T1 HRP20131203AT HRP20131203T HRP20131203T1 HR P20131203 T1 HRP20131203 T1 HR P20131203T1 HR P20131203A T HRP20131203A T HR P20131203AT HR P20131203 T HRP20131203 T HR P20131203T HR P20131203 T1 HRP20131203 T1 HR P20131203T1
- Authority
- HR
- Croatia
- Prior art keywords
- virus
- duck
- cells
- bird
- cell lines
- Prior art date
Links
- 241000272525 Anas platyrhynchos Species 0.000 title claims 9
- 238000004519 manufacturing process Methods 0.000 title claims 3
- 210000000130 stem cell Anatomy 0.000 title 1
- 229960004854 viral vaccine Drugs 0.000 title 1
- 241000700605 Viruses Species 0.000 claims 24
- 210000004027 cell Anatomy 0.000 claims 20
- 238000000034 method Methods 0.000 claims 16
- 241000271566 Aves Species 0.000 claims 10
- 241000701161 unidentified adenovirus Species 0.000 claims 7
- 241001430294 unidentified retrovirus Species 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000001963 growth medium Substances 0.000 claims 5
- 235000015097 nutrients Nutrition 0.000 claims 5
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims 4
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 3
- 241000700618 Vaccinia virus Species 0.000 claims 3
- 238000004113 cell culture Methods 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 206010022000 influenza Diseases 0.000 claims 3
- 210000001161 mammalian embryo Anatomy 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 241000193057 Biziura lobata Species 0.000 claims 2
- 241000272201 Columbiformes Species 0.000 claims 2
- 241000710831 Flavivirus Species 0.000 claims 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 2
- 241000125945 Protoparvovirus Species 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 230000001464 adherent effect Effects 0.000 claims 2
- 239000007640 basal medium Substances 0.000 claims 2
- 208000011090 bird disease Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 241000272814 Anser sp. Species 0.000 claims 1
- 241000272517 Anseriformes Species 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 208000027312 Bursal disease Diseases 0.000 claims 1
- 241000178270 Canarypox virus Species 0.000 claims 1
- 241000712083 Canine morbillivirus Species 0.000 claims 1
- 241001502567 Chikungunya virus Species 0.000 claims 1
- 241001533384 Circovirus Species 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 241000336325 Duck infectious anemia virus Species 0.000 claims 1
- 241000684283 Duck parvovirus Species 0.000 claims 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241000700662 Fowlpox virus Species 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241000608292 Mayaro virus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 241000711408 Murine respirovirus Species 0.000 claims 1
- HPFXACZRFJDURI-KTKRTIGZSA-N N-oleoylglycine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCC(O)=O HPFXACZRFJDURI-KTKRTIGZSA-N 0.000 claims 1
- 241000702244 Orthoreovirus Species 0.000 claims 1
- 241000287127 Passeridae Species 0.000 claims 1
- 241000286209 Phasianidae Species 0.000 claims 1
- 241000287531 Psittacidae Species 0.000 claims 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 claims 1
- 241000711897 Rinderpest morbillivirus Species 0.000 claims 1
- 241000710942 Ross River virus Species 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 241000710961 Semliki Forest virus Species 0.000 claims 1
- 241000710960 Sindbis virus Species 0.000 claims 1
- 241000713896 Spleen necrosis virus Species 0.000 claims 1
- 241000287181 Sturnus vulgaris Species 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 241000710951 Western equine encephalitis virus Species 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 claims 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 claims 1
- 239000012228 culture supernatant Substances 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 240000001854 junco Species 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 230000017448 oviposition Effects 0.000 claims 1
- 244000144977 poultry Species 0.000 claims 1
- 230000001566 pro-viral effect Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000003153 stable transfection Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000004114 suspension culture Methods 0.000 claims 1
- 201000010740 swine influenza Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 238000003146 transient transfection Methods 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18451—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (13)
1. Postupak dobivanja kontinuiranih diploidnih ptičjih staničnih linija iz ptičjih embrijskih matičnih stanica (ES), gdje su te ptičje stanične linije sposobne proliferirati u bazalnom mediju bez prisutnosti faktora rasta i hranjivog sloja, i ne proizvode za replikaciju kompetentne endogene čestice retrovirusa, taj postupak obuhvaća korake:
a) izoliranje ptičjeg embrija u razvojnoj fazi oko ovipozicije, pri čemu se ta ptica izabire iz reda Anseriformes i genom te ptice ne sadrži endogene pro-virusne sekvence sklone proizvodnji za replikaciju kompetentnih endogenih čestica retrovirusa;
b) suspendiranje ptičjih embrijskih matičnih (ES) stanica dobivenih disocijacijom embrija u koraku a) u bazalnom mediju kulture s dodatkom:
- Inzulinu sličnog faktora rasta 1 (IGF-1) i cilijarnog neurotrofnog faktora (CNTF); i
- životinjskog seruma;
c) sijanje suspenzije ES stanica dobivenih u koraku b) na sloju hranjivih stanica i daljnji uzgoj kulture ES stanica kroz barem jedan pasaž;
d) uklanjanje IGF-1 i CNTF iz medija kulture, i daljnji uzgoj kulture stanice kroz barem jedan pasaž;
e) progresivno snižavanje koncentracije hranjivih stanica u mediju kulture tako da se dobije potpuno uklanjanje hranjivog sloja nakon nekoliko pasaža, i daljnji uzgoj kulture stanica;
f) dobivanje adherentnih kontinuiranih diploidnih ptičjih staničnih linija iz ES stanica koje su sposobne proliferirati u bazalnom mediju bez prisutnosti faktora rasta i hranjivog sloja, i gdje te ptičje stanične linije ne proizvode za replikaciju kompetentne endogene čestice retrovirusa.
2. Postupak prema zahtjevu 1, gdje se nakon koraka e) koncentracija životinjskog seruma u mediju kulture progresivno smanjuje tako da se dobije potpuno uklanjanje životinjskog seruma nakon nekoliko pasaža.
3. Postupak prema bilo kojem od zahtjeva 1 ili 2, gdje su te adherentne ptičje stanične linije prilagođene uvjetima suspenzije u kulturi.
4. Postupak prema bilo kojem od zahtjeva 1 do 3 gdje se uklanjanje faktora rasta IGF-1 i CNTF iz medija kulture u koraku d) provodi istodobno.
5. Postupak prema bilo kojem od zahtjeva 1 do 4 gdje je ta ptica patka.
6. Postupak prema zahtjevu 5, gdje je ta patka pekinška patka.
7. Postupak prema zahtjevu 5 gdje je ta patka mošusna patka.
8. Postupak prema zahtjevu 7 gdje se jaje te mošusne patke inkubira kako bi sazrjelo prije izoliranja pačjeg embrija.
9. Postupak prema bilo kojem od zahtjeva 1 do 8 gdje te kontinuirane diploidne ptičje stanične linije imaju barem jednu od sljedećih karakteristika:
- visoki omjer jezgre prema citoplazmi,
- aktivnost endogene telomeraze,
- promjer oko 10mm;
- vrijeme udvostručavanja populacije oko 30 sati ili manje na 37°C;
- te stanice eksprimiraju jedan ili više dodatnih markera izabranih iz grupe koja obuhvaća alkalnu fosfatazu, SSEA-1, EMA-1, ENS-1, i
gdje te stanice ne proizvode za replikaciju kompetentne endogene čestice retrovirusa.
10. Postupak replikacije virusa u kontinuiranoj diploidnoj ptičjoj staničnoj liniji dobivenoj postupkom prema bilo kojem od zahtjeva 1 do 9, obuhvaća korake:
a) infekcija tih ptičjih stanica virusom od interesa;
b) uzgoj kulture tih inficiranih ptičjih stanica radi replikacije tog virusa;
c) uzimanje virusa iz supernatanta stanične kulture i/ili unutrašnjosti tih stanica.
11. Postupak prema zahtjevu 10, gdje se taj virus izabire iz grupe koja obuhvaća pox viruse, ortomiksoviruse, paramiksoviruse, herpes viruse, hepa dna viruse, adenoviruse, parvoviruses, reoviruse, cirkoviruse, koronaviruse, flaviviruse, togaviruse, birnaviruse i retroviruse.
12. Postupak prema zahtjevu 10 gdje se virus izabire iz grupe koja obuhvaća:
- pox virus ili rekombinantni pox virus izabran iz grupe koja obuhvaća Modificirani vakcinija Ankara (MVA) virus, Lister-Elstree vakcinija virus, LC16m8 vakcinija virus, CVI78 vakcinija virus, virus boginja peradi, virus boginja kanarinaca (tj. ALVAC), NYVAC, virus boginja ptice junko, virus boginja ptice mina, virus boginja goluba, virus boginja papiga, virus boginja prepelica, virus boginja vrabaca, virus boginja čvorka, virus boginja purana;
- paramiksovirus ili rekombinantni paramiksovirus izabran iz grupe koja obuhvaća virus ospica, virus zaušnjaka, rubela virus, Sendai virus, Respiratorni Sincicijski virus (RSV), humani para-influenca tipovi I i III, virus goveđe kuge, virus pseće kuge, virus Newcastle bolesti, virus pačje para-influence;
- ortomiksovirus, rekombinantni ortomiksovirus ili reasortirani orthomiksovirus izabran između virusa ljudske gripe, virusa ptičje gripe, virusa svinjske gripe, virusa konjske gripe, virusa mačje gripe;
- togavirus poželjno izabran između Sindbis virusa, virusa Semliki šume, O’nyong’nyong virusa, Chikungunya virusa, Mayaro virusa, virusa rijeke Ross, virus istočnog konjskog encefalitisa, virus zapadnog konjskog encefalitisa, virus venecuelanskog konjskog encefalitisa, ili njihov rekombinantni togavirus;
- retrovirus izabran između virusa retikulo-endotelioze, virus pačje zarazne anemije, virus nekroze pačje slezene, ili njihov rekombinantni retrovirus;
- pačji parvovirus ili njegov rekombinantni parvovirus;
- adenovirus izabran između adenovirusa peradi, adenovirusa guske, pačjeg adenovirusa i golubljeg adenovirusa ili njihovog rekombinantnog adenovirusa;
- birnavirus poželjno virus zarazne burzalne bolesti; i
- flavivirus poželjno izabran između Dengue virusa, virusa japanskog encefalitisa i virusa zapadnog Nila.
13. Postupak proizvodnje rekombinantnih proteina i peptida, obuhvaća korake:
a. genetičko modificiranje kontinuiranih diploidnih ptičjih staničnih linija dobivenih u postupku prema bilo kojem od zahtjeva 1 do 9, prijelaznom ili stabilnom transfekcijom vektora ekspresije;
b. odabir tih genetički modificiranih ptičjih staničnih linija koje eksprimiraju rekombinantne proteine ili peptide; i
c. pročišćavanje rekombinantnih proteina ili peptida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07300979A EP1985305A1 (en) | 2007-04-24 | 2007-04-24 | Duck embryonic derived stem cell lines for the production of viral vaccines |
PCT/EP2008/054912 WO2008129058A1 (en) | 2007-04-24 | 2008-04-23 | Duck embryonic derived stem cell lines for the production of viral vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20131203T1 true HRP20131203T1 (hr) | 2014-02-14 |
Family
ID=38521810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20131203AT HRP20131203T1 (hr) | 2007-04-24 | 2013-12-17 | Linije matiäśnih stanica iz paäśjih embrija za proizvodnju virusnih cjepiva |
Country Status (23)
Country | Link |
---|---|
US (4) | US20100062489A1 (hr) |
EP (4) | EP1985305A1 (hr) |
JP (1) | JP5539185B2 (hr) |
KR (2) | KR101624678B1 (hr) |
CN (1) | CN101668539B (hr) |
AU (1) | AU2008240708B2 (hr) |
BR (1) | BRPI0809842B8 (hr) |
CA (1) | CA2684845C (hr) |
CY (1) | CY1114736T1 (hr) |
DK (1) | DK2150275T3 (hr) |
EA (1) | EA021064B1 (hr) |
ES (2) | ES2442009T3 (hr) |
HK (1) | HK1140964A1 (hr) |
HR (1) | HRP20131203T1 (hr) |
IL (1) | IL201679A (hr) |
MX (1) | MX343247B (hr) |
MY (1) | MY151119A (hr) |
NZ (1) | NZ581321A (hr) |
PL (1) | PL2150275T3 (hr) |
PT (1) | PT2150275E (hr) |
SI (1) | SI2150275T1 (hr) |
WO (1) | WO2008129058A1 (hr) |
ZA (1) | ZA200908152B (hr) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
EP2054507A1 (en) * | 2006-08-09 | 2009-05-06 | Vivalis | Method of production of transgenic avian using embryonic stem cells |
EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
KR101445433B1 (ko) | 2008-02-25 | 2014-09-26 | 백스터 인터내셔널 인코포레이티드 | 연속 세포주 제조 방법 |
CA2741961A1 (en) * | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
ES2539045T3 (es) | 2009-01-19 | 2015-06-25 | Innate Pharma | Anticuerpos anti-KIR3D |
EP2393922A1 (en) | 2009-02-06 | 2011-12-14 | GlaxoSmithKline Biologicals S.A. | Purification of virus or viral antigens by density gradient ultracentrifugation |
CA2760657A1 (en) * | 2009-05-08 | 2010-11-11 | Glaxosmithkline Biologicals S.A. | Method for producing virus from cell culture involving homogenization |
EP2429580A1 (en) * | 2009-05-12 | 2012-03-21 | Transgene SA | Method for orthopoxvirus production and purification |
GB0918830D0 (en) | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
GB0919117D0 (en) * | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
CA3177833A1 (en) | 2009-12-15 | 2011-06-15 | University Of Saskatchewan | Vaccines for inclusion body hepatitis |
CN102120983B (zh) * | 2010-01-07 | 2013-04-03 | 中国农业科学院北京畜牧兽医研究所 | 北京鸭表皮干细胞的分离和培养方法 |
US20120309056A1 (en) | 2010-02-04 | 2012-12-06 | Leon Arnaud | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
FR2956409A1 (fr) | 2010-02-15 | 2011-08-19 | Univ Claude Bernard Lyon | Procedes pour optimiser la production virale par l'inactivation ou l'inhibition du gene hipk2 et cellules modifiees pour la production virale |
EP2552490A4 (en) * | 2010-03-26 | 2013-12-18 | Emergent Product Dev Gaithersburg Inc | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF |
ES2562818T3 (es) | 2010-05-03 | 2016-03-08 | Glaxosmithkline Biologicals S.A. | Procedimiento de inactivación del virus de la gripe |
GB201011502D0 (en) | 2010-07-08 | 2010-08-25 | Glaxosmithkline Biolog Sa | Novel process |
NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
AU2011314630B2 (en) * | 2010-10-15 | 2016-02-04 | Km Biologics Co., Ltd. | Recombinant vaccinia virus having hemagglutinin protein genes derived from novel influenza viruses |
FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
WO2013000982A1 (en) | 2011-06-27 | 2013-01-03 | Vivalis | Method for screening cells |
WO2013044298A1 (en) | 2011-09-30 | 2013-04-04 | Cephalon Australia Pty Ltd | Antibodies against tl1a and uses thereof |
EP2771351B1 (en) | 2011-10-28 | 2017-06-14 | Patrys Limited | Pat-lm1 epitopes and methods for using same |
CN103157107A (zh) * | 2011-12-14 | 2013-06-19 | 普莱柯生物工程股份有限公司 | 用连续传代细胞系生产鸡马立克氏病疫苗及方法 |
AR089231A1 (es) * | 2011-12-15 | 2014-08-06 | Amgen Inc | Metodo de floculacion |
EP2660316A1 (en) | 2012-05-02 | 2013-11-06 | Helmholtz-Zentrum für Infektionsforschung GmbH | Avian cell line and its use in production of protein |
WO2014080676A1 (ja) * | 2012-11-22 | 2014-05-30 | 旭化成メディカル株式会社 | 高感染価のパルボウイルスの生産方法 |
CN105531289B (zh) | 2013-02-01 | 2019-02-22 | 树突细胞生物科技有限公司 | 抗cd83抗体及其用途 |
EP4219552A3 (en) | 2013-02-07 | 2023-09-13 | CSL Ltd. | Il-11r binding proteins and uses thereof |
FR3008992A1 (fr) * | 2013-07-25 | 2015-01-30 | Agronomique Inst Nat Rech | Procede de selection d'une lignee cellulaire permissive pour la replication de virus aviaires |
ES2778928T3 (es) * | 2013-08-30 | 2020-08-12 | Glaxosmithkline Biologicals Sa | Producción a gran escala de virus en cultivos celulares |
CN105177176A (zh) * | 2014-06-13 | 2015-12-23 | 亚宝药业太原制药有限公司 | 一种腺病毒滴度的检测方法 |
CA3190510A1 (en) | 2014-07-16 | 2016-01-21 | Transgene Sa | Oncolytic virus for expression of immune checkpoint modulators |
FR3025107B1 (fr) | 2014-08-29 | 2018-10-05 | Calixar | Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations |
WO2016061632A1 (en) | 2014-10-23 | 2016-04-28 | La Trobe University | Fn14-binding proteins and uses thereof |
CA2965170A1 (en) | 2014-10-23 | 2016-04-28 | Dendrocyte Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
JP6956635B2 (ja) | 2014-12-17 | 2021-11-02 | フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ | ウィルソン病及び他の状態の処置に使用するための核酸構築物及び遺伝子治療ベクター |
KR102526616B1 (ko) | 2014-12-17 | 2023-04-27 | 푼다시온 파라 라 인베스티가시온 메디카 아플리카다 | 윌슨병 및 기타 병태의 치료에 사용되기 위한 핵산 구조물 및 유전자 치료용 벡터 |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
BR112018014028A2 (pt) | 2016-01-11 | 2019-02-05 | Forty Seven Inc | anticorpos monoclonais anti-cd47 humanizados, de camundongo ou quimérico |
US20190134190A1 (en) | 2016-05-04 | 2019-05-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
CN107137704B (zh) * | 2016-08-20 | 2020-02-21 | 山东信得科技股份有限公司 | 一种鸭2型腺病毒灭活疫苗 |
WO2018060368A2 (en) | 2016-09-28 | 2018-04-05 | Bavarian Nordic A/S | Compositions and methods for enhancing the stability of transgenes in poxviruses |
US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
CN106692964A (zh) * | 2016-12-05 | 2017-05-24 | 扬州大学 | 一种血清4型禽腺病毒灭活苗及其制备方法 |
WO2018122088A1 (en) | 2016-12-28 | 2018-07-05 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
CN107058243A (zh) * | 2017-03-23 | 2017-08-18 | 华南农业大学 | 一种马立克氏病毒的悬浮培养方法 |
JP7406377B2 (ja) | 2017-05-15 | 2023-12-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定なウイルス含有組成物 |
WO2018210804A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
CA3066060A1 (en) | 2017-06-07 | 2018-12-13 | Wild Type, Inc. | Ex vivo meat production |
IL271558B2 (en) | 2017-06-21 | 2024-01-01 | Transgene | A vaccine tailored to the individual |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
CN107794248A (zh) * | 2017-10-24 | 2018-03-13 | 广州齐志生物工程设备有限公司 | 一种用微载体悬浮培养犬瘟热病毒的方法 |
KR102121042B1 (ko) * | 2017-12-06 | 2020-06-09 | 이정복 | 조류의 에그로부터 분리한 세포인 배반엽 전분화능세포, 신경줄기세포, 배아섬유아세포 컨디션드 배지를 유효성분으로 하는 세포 증식, 피부재생 및 주름 개선용 배지 조성물 |
CN108220227A (zh) * | 2017-12-27 | 2018-06-29 | 华农(肇庆)生物产业技术研究院有限公司 | 一种通过全悬浮传代细胞系悬浮培养新城疫病毒的方法 |
CN108159412A (zh) * | 2018-01-12 | 2018-06-15 | 华农(肇庆)生物产业技术研究院有限公司 | 一种生产细胞源鸡新城疫、禽流感二联灭活疫苗的方法及其产品 |
CN108261543B (zh) * | 2018-02-08 | 2019-03-08 | 华农(肇庆)生物产业技术研究院有限公司 | 传代细胞源nd、ib、ai三联灭活疫苗的制备方法及其应用 |
CN108187039A (zh) * | 2018-03-29 | 2018-06-22 | 山东信得动物疫苗有限公司 | 一种禽流感灭活疫苗生产工艺及产品 |
WO2019219649A1 (en) | 2018-05-14 | 2019-11-21 | Vivet Therapeutics | Gene therapy vectors comprising s/mar sequences |
WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
US20210275662A1 (en) | 2018-07-13 | 2021-09-09 | Valneva Se | Method for rescuing and producing a virus in avian cells |
EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
CN108977554B (zh) * | 2018-09-05 | 2021-08-31 | 湖北省农业科学院畜牧兽医研究所 | 蛋鸭环状RNA circ_13034及其检测试剂、方法与应用 |
US20210187100A1 (en) | 2018-09-06 | 2021-06-24 | Bavarian Nordic A/S | Storage Improved Poxvirus Compositions |
KR20210086638A (ko) | 2018-10-12 | 2021-07-08 | 비베트 테라퓨틱스 | 진행성 가족성 간내 담즙정체 3형 (pfic3)의 치료를 위한 코돈-최적화 전이유전자 |
EP3877000A1 (en) | 2018-11-07 | 2021-09-15 | Vivet Therapeutics | Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2) |
TW202039854A (zh) | 2018-11-16 | 2020-11-01 | 美商編碼製藥公司 | 治療威爾遜氏病的組合物和方法 |
CN113474449A (zh) * | 2018-11-23 | 2021-10-01 | 瓦尔尼瓦公司 | 包括禽类干细胞的食物产品 |
WO2020108735A1 (en) | 2018-11-26 | 2020-06-04 | Blink Biomedical Sas | Antibodies to cytomegalovirus interleukin-10 |
CN113423815A (zh) * | 2018-12-06 | 2021-09-21 | 创赏有限公司 | 非动物来源培养基上的细菌生长 |
EP3893668A4 (en) | 2018-12-12 | 2022-08-10 | Wild Type, Inc. | SYNTHETIC FOOD COMPOSITIONS |
WO2020136235A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | M2-defective poxvirus |
CN109593729A (zh) * | 2018-12-29 | 2019-04-09 | 肇庆大华农生物药品有限公司 | 一种禽减蛋综合征病毒培养方法及其在疫苗中的应用 |
MX2021006115A (es) * | 2019-01-17 | 2021-07-07 | Boehringer Ingelheim Animal Health Usa Inc | Medio libre de suero para produccion de vacuna aviar y usos del mismo. |
JP7212588B2 (ja) | 2019-06-20 | 2023-01-25 | オルガノ株式会社 | 水処理装置 |
AU2020299718A1 (en) | 2019-07-02 | 2022-02-24 | Fundacion Para La Investigacion Medica Aplicada | cPLA2e inducing agents and uses thereof |
BR112022017438A2 (pt) | 2020-03-12 | 2022-10-18 | Bavarian Nordic As | Composições que melhoram a estabilidade do poxvírus |
US20230256057A1 (en) | 2020-07-13 | 2023-08-17 | Transgene | Treatment of immune depression |
EP4192961A2 (en) | 2020-08-06 | 2023-06-14 | Fundacion para la Investigacion Medica Aplicada | Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy |
US20230265456A1 (en) | 2020-08-10 | 2023-08-24 | Fundacion Para La Investigacion Medica Aplicada | Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis |
CN112094819B (zh) * | 2020-08-13 | 2022-10-14 | 浙江美保龙生物技术有限公司 | 一种鸡传染性法氏囊病毒的全悬浮培养方法 |
EP4225782A1 (en) | 2020-10-09 | 2023-08-16 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
CN112442486B (zh) * | 2020-11-05 | 2023-02-10 | 上海奥浦迈生物科技股份有限公司 | 一种维持体外培养cho dg44细胞后期活率的培养基及其应用 |
CN113699119A (zh) * | 2020-12-10 | 2021-11-26 | 华农(肇庆)生物产业技术研究院有限公司 | 一种新城疫病毒及疫苗的无血清全悬浮培养制备方法 |
US20240091382A1 (en) | 2020-12-23 | 2024-03-21 | Vivet Therapeutics | Minimal bile acid inducible promoters for gene therapy |
WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
CN113278595B (zh) * | 2021-04-28 | 2023-05-09 | 重庆永健生物技术有限责任公司 | 一种鸭腺病毒3型菌株、鸭腺病毒卵黄抗体及其制备方法和应用 |
WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
TW202321458A (zh) | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
CA3234666A1 (en) | 2021-10-28 | 2023-05-04 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
CN115449502B (zh) * | 2022-08-15 | 2023-10-20 | 广东省华晟生物技术有限公司 | 无血清全悬浮培养型bhk-21-c细胞株及其构建方法与应用 |
WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US534740A (en) * | 1895-02-26 | Indicating door-bell | ||
JP2740320B2 (ja) | 1988-08-04 | 1998-04-15 | アムラド・コーポレイション・リミテッド | 胚幹細胞のインビトロ増殖 |
US5162215A (en) | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
JPH05227947A (ja) | 1992-01-14 | 1993-09-07 | Rikagaku Kenkyusho | 鳥類原始生殖細胞の分離方法 |
AU3597093A (en) | 1992-01-27 | 1993-09-01 | Embrex Inc. | Gene transfer in poultry by introduction of embryo cells (in ovo) |
US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
WO1994003585A1 (en) | 1992-08-04 | 1994-02-17 | Commonwealth Scientific And Industrial Research Organisation | A method for maintaining embryonic stem cells and avian factor useful for same |
US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
US5589458A (en) | 1992-11-13 | 1996-12-31 | Thomas Jefferson University | Compounds that inhibit T cell proliferation and methods for using the same |
FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
JPH0924997A (ja) | 1995-07-11 | 1997-01-28 | Tokico Ltd | 出荷装置 |
AU4751697A (en) | 1996-10-10 | 1998-05-05 | Douglas Danner | Animal cell culture media comprising plant-derived nutrients |
ES2224210T3 (es) | 1996-11-12 | 2005-03-01 | Pfizer Inc. | Vacuna de neospora viva atenuada. |
ES2255174T3 (es) | 1997-08-04 | 2006-06-16 | Univ. Massachusetts, A Public Inst. Higher Educ. Of Commonwealth Massach. Repr By Its Amherst Campus | Produccion de lineas de celulas germinales embrionarias (eg) aviares por cultivo prolongado de pgc, y uso de las mismas para clonacion y quimerizacion. |
EP1616943A1 (en) | 1997-08-04 | 2006-01-18 | University of Massachusetts, a Public Institution of Higher Education of The Commonwealth of Massachusetts, | Avian primordial germ cell (PGC) cell line and a method for long term culturing thereof |
US6406909B1 (en) | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
CA2359775C (en) | 1999-02-11 | 2007-09-18 | Jae Yong Han | Avian pluripotent embryonic germ cell line |
DE19947407C2 (de) | 1999-10-01 | 2002-08-01 | Bayerische Motoren Werke Ag | Datenbussystem für Kraftfahrzeuge |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
DK2287288T3 (da) | 2002-07-09 | 2013-01-07 | Baxter Int | Medium frit for animalsk protein til dyrkning af celler |
DE602004027141D1 (de) * | 2003-07-22 | 2010-06-24 | Vivalis | Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien |
EP1500699A1 (en) * | 2003-07-22 | 2005-01-26 | Vivalis | Production of vaccinia virus with adherent or non adherent avian cell lines |
EP1528101A1 (en) * | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
PT1979474E (pt) * | 2006-01-05 | 2010-10-22 | Transgene Sa | Transcriptase inversa da telomerase aviária |
WO2007135133A1 (en) * | 2006-05-19 | 2007-11-29 | Vivalis | Avian cell lines derived from primordial germ cells useful for the production of substances of interest |
EP2054507A1 (en) | 2006-08-09 | 2009-05-06 | Vivalis | Method of production of transgenic avian using embryonic stem cells |
EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
-
2007
- 2007-04-24 EP EP07300979A patent/EP1985305A1/en not_active Withdrawn
-
2008
- 2008-04-23 ES ES08736491.5T patent/ES2442009T3/es active Active
- 2008-04-23 US US12/597,486 patent/US20100062489A1/en not_active Abandoned
- 2008-04-23 ES ES12187538.9T patent/ES2574827T3/es active Active
- 2008-04-23 KR KR1020097024511A patent/KR101624678B1/ko active IP Right Grant
- 2008-04-23 PL PL08736491T patent/PL2150275T3/pl unknown
- 2008-04-23 AU AU2008240708A patent/AU2008240708B2/en active Active
- 2008-04-23 MX MX2009011505A patent/MX343247B/es active IP Right Grant
- 2008-04-23 WO PCT/EP2008/054912 patent/WO2008129058A1/en active Application Filing
- 2008-04-23 NZ NZ581321A patent/NZ581321A/en unknown
- 2008-04-23 JP JP2010504672A patent/JP5539185B2/ja active Active
- 2008-04-23 KR KR1020157005296A patent/KR20150036788A/ko not_active Application Discontinuation
- 2008-04-23 BR BRPI0809842A patent/BRPI0809842B8/pt active IP Right Grant
- 2008-04-23 EP EP08736491.5A patent/EP2150275B1/en active Active
- 2008-04-23 EP EP12187538.9A patent/EP2572727B1/en active Active
- 2008-04-23 EA EA200970996A patent/EA021064B1/ru unknown
- 2008-04-23 CA CA2684845A patent/CA2684845C/en active Active
- 2008-04-23 DK DK08736491.5T patent/DK2150275T3/da active
- 2008-04-23 CN CN200880013257.3A patent/CN101668539B/zh active Active
- 2008-04-23 SI SI200831121T patent/SI2150275T1/sl unknown
- 2008-04-23 MY MYPI20094422 patent/MY151119A/en unknown
- 2008-04-23 EP EP12187539A patent/EP2572728A1/en not_active Withdrawn
- 2008-04-23 PT PT87364915T patent/PT2150275E/pt unknown
-
2009
- 2009-10-22 IL IL201679A patent/IL201679A/en active IP Right Grant
- 2009-11-19 ZA ZA200908152A patent/ZA200908152B/xx unknown
-
2010
- 2010-08-06 HK HK10107529.3A patent/HK1140964A1/xx unknown
-
2013
- 2013-11-01 US US14/069,423 patent/US9260694B2/en active Active
- 2013-12-17 HR HRP20131203AT patent/HRP20131203T1/hr unknown
- 2013-12-27 CY CY20131101167T patent/CY1114736T1/el unknown
-
2016
- 2016-02-02 US US15/013,079 patent/US9822345B2/en active Active
-
2017
- 2017-10-17 US US15/785,530 patent/US20180135026A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20131203T1 (hr) | Linije matiäśnih stanica iz paäśjih embrija za proizvodnju virusnih cjepiva | |
JP2010524482A5 (hr) | ||
JP5031726B2 (ja) | 懸濁鳥類胚性幹細胞株においてウイルスワクチンを製造する方法 | |
Huang et al. | Recombinant Newcastle disease virus as a vaccine vector | |
BRPI0811787B1 (pt) | usos de uma célula imortalizada e processo para imortalizar uma célula aviária | |
PT1646715E (pt) | Produção de poxvírus com linhagem das células aviarias aderentes ou não aderentes | |
Engel-Herbert et al. | Characterization of a recombinant Newcastle disease virus expressing the green fluorescent protein | |
CN107109436A (zh) | 病毒载体、细胞及构建体 | |
CN104704112A (zh) | 传染性流感病毒的生产 | |
CN1330376C (zh) | 重组鸡痘病毒联合疫苗 |